- Home
- GLUE vs ZTR Comparison
GLUE vs ZTR Comparison
Compare GLUE & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- ZTR
- Stock Information
- Founded
- GLUE 2019
- ZTR 1988
- Country
- GLUE United States
- ZTR Australia
- Employees
- GLUE N/A
- ZTR N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- ZTR Investment Managers
- Sector
- GLUE Health Care
- ZTR Finance
- Exchange
- GLUE Nasdaq
- ZTR Nasdaq
- Market Cap
- GLUE 351.2M
- ZTR 349.4M
- IPO Year
- GLUE 2021
- ZTR N/A
- Fundamental
- Price
- GLUE $4.80
- ZTR $6.37
- Analyst Decision
- GLUE Buy
- ZTR
- Analyst Count
- GLUE 2
- ZTR 0
- Target Price
- GLUE $13.50
- ZTR N/A
- AVG Volume (30 Days)
- GLUE 369.2K
- ZTR 219.4K
- Earning Date
- GLUE 08-07-2025
- ZTR 01-01-0001
- Dividend Yield
- GLUE N/A
- ZTR 12.09%
- EPS Growth
- GLUE N/A
- ZTR N/A
- EPS
- GLUE 0.29
- ZTR N/A
- Revenue
- GLUE $177,986,000.00
- ZTR N/A
- Revenue This Year
- GLUE $83.76
- ZTR N/A
- Revenue Next Year
- GLUE N/A
- ZTR N/A
- P/E Ratio
- GLUE $16.32
- ZTR N/A
- Revenue Growth
- GLUE 2990.57
- ZTR N/A
- 52 Week Low
- GLUE $3.50
- ZTR $4.50
- 52 Week High
- GLUE $12.40
- ZTR $6.60
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- ZTR 64.07
- Support Level
- GLUE $4.54
- ZTR $6.27
- Resistance Level
- GLUE $4.93
- ZTR $6.35
- Average True Range (ATR)
- GLUE 0.21
- ZTR 0.04
- MACD
- GLUE 0.06
- ZTR 0.01
- Stochastic Oscillator
- GLUE 81.43
- ZTR 85.06
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.